Literature DB >> 12428202

Disorders of androgen action.

Charles Sultan1, Serge Lumbroso, Françoise Paris, Claire Jeandel, B Terouanne, Charles Belon, F Audran, N Poujol, V Georget, J Gobinet, S Jalaguier, G Auzou, J C Nicolas.   

Abstract

Disorders of androgen action are the main cause of male pseudohermaphroditism and include 5alphaR deficiency and androgen receptor defects. 5alphaR deficiency is characterized by female genitalia with some degree of masculinization, clitoromegaly, and severely bifid scrotum corresponding to the so-called pseudovaginal perineoscrotal hypospadias. At the onset of puberty, increased muscle mass, development of pubic hair, and phallic growth are associated with the acquisition of male gender identity. Normal or increased levels of testosterone and an elevated testosterone-to-dihydrotestosterone ratio after human chorionic gonadotropin stimulation testing suggest 5alphareductase deficiency, and the diagnosis can be ascertained by identifying the mutation in the 5alphaR-2 gene. Whatever the patient's age at diagnosis, psychological evaluation with 5alphaRD is vital. Androgen receptor defects encompass two clinical expressions: the complete and partial androgen insensitivity syndromes. Complete androgen insensitivity syndrome should be suspected at birth in the presence of inguinal hernia in a girl without genital ambiguity. At puberty, the sign of alert is primary amenorrhea with normal female phenotype and harmonious mammary development but no pubic hair growth. Partial androgen insensitivity syndrome covers a wide spectrum of undervirilized phenotypes ranging from clitoromegaly at birth to infertile men. In all cases, complementary investigations should include plasma testosterone and luteinizing hormone as well as androgen-binding capacity in cultured genital skin fibroblasts. Diagnosis is confirmed by identification of the androgen receptor gene mutation. Although patients with complete androgen insensitivity syndrome are raised as females, patients with partial androgen insensitivity syndrome should be managed according to age at diagnosis, response to treatment with exogenous androgens, and the presence of an androgen gene mutation. Gonadectomy in complete androgen insensitivity syndrome should be performed before puberty, and androgen substitution may improve the development of external genitalia in some patients with partial androgen insensitivity syndrome. Psychological follow-up is necessary.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12428202     DOI: 10.1055/s-2002-35386

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  6 in total

Review 1.  Towards improved genetic diagnosis of human differences of sex development.

Authors:  Emmanuèle C Délot; Eric Vilain
Journal:  Nat Rev Genet       Date:  2021-06-03       Impact factor: 53.242

2.  Mayer-rokitansky-kuster-hauser syndrome: embryology, genetics and clinical and surgical treatment.

Authors:  Alfonsa Pizzo; Antonio Simone Laganà; Emanuele Sturlese; Giovanni Retto; Annalisa Retto; Rosanna De Dominici; Domenico Puzzolo
Journal:  ISRN Obstet Gynecol       Date:  2013-02-04

Review 3.  The Mayer-Rokitansky-Küster-Hauser syndrome (congenital absence of uterus and vagina)--phenotypic manifestations and genetic approaches.

Authors:  Daniel Guerrier; Thomas Mouchel; Laurent Pasquier; Isabelle Pellerin
Journal:  J Negat Results Biomed       Date:  2006-01-27

Review 4.  Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome.

Authors:  Karine Morcel; Laure Camborieux; Daniel Guerrier
Journal:  Orphanet J Rare Dis       Date:  2007-03-14       Impact factor: 4.123

Review 5.  Role of androgens in cardiovascular pathology.

Authors:  Dimitry A Chistiakov; Veronika A Myasoedova; Alexandra A Melnichenko; Andrey V Grechko; Alexander N Orekhov
Journal:  Vasc Health Risk Manag       Date:  2018-10-15

6.  Cytogenetic and molecular diagnosis of Fanconi anemia revealed two hidden phenotypes: Disorder of sex development and cerebro-oculo-facio-skeletal syndrome.

Authors:  Abir Ben Haj Ali; Ahlem Amouri; Marwa Sayeb; Saloua Makni; Wajih Hammami; Chokri Naouali; Hamza Dallali; Lilia Romdhane; Anu Bashamboo; Kenneth McElreavey; Sonia Abdelhak; Olfa Messaoud
Journal:  Mol Genet Genomic Med       Date:  2019-05-23       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.